Phase 2Active, not recruiting
Safety and Efficacy of Empagliflozin in Hemodialysis (SEED)
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Empagliflozin Among Patients Initiating Hemodialysis for the Treatment of End-Stage Kidney Disease
- Sponsor
- NYU Langone Health (Academic or other)
- Enrollment
- 60 planned
- Conditions
- End Stage Renal Disease
- Interventions
- Empagliflozin 10 MG; Placebo
- Ages
- adults, older adults
- Registry
- NCT05786443
Full record on ClinicalTrials.gov
From the registry
A 12-week, phase II, randomized, double-blind, placebo-controlled, multi-center study to assess the safety, tolerability, and preliminary efficacy of empagliflozin versus placebo among patients initiating hemodialysis (n=60) for the treatment of end-stage kidney disease.
Primary outcomes
- Change in Extracellular Volume from Baseline to 12 Weeks
- Change in Intracellular Volume from Baseline to 12 Weeks
- Change in Total Body Water from Baseline to 12 Weeks
- Change in 24-Hour Urine Volume from Baseline to 12 Weeks
History
Primary completion expected
Now active, not recruiting
, from Recruiting to Active, not recruiting
Last registry update
Started
Registered